Lunaphore highlights novel spatial biology research at SITC 2021
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced new research from collaborators at the University of Birmingham, who characterized the inflammatory response associated with a complication from maternal COVID-19 infection, using COMET™, Lunaphore’s all-in-one staining and imaging platform for high-throughput, hyperplex immunofluorescence. The results will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place November 10-14, 2021 virtually and in-person at the Walter E. Washington Convention Center in Washington, D.C. Lunaphore will also hold product demonstrations of LabSat® and COMET™ at booth #408.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109006114/en/
Photo: Lunaphore
Using spatial biology tools to characterize COVID-19 placentitis
A proportion of maternal COVID-19 infections are complicated by COVID-19 placentitis, an inflammatory response that often leads to fetal death. However, there has been limited research to-date on the processes that drive this condition and its underlying pathology.
In a sponsored symposium, Matthew Pugh, FRCPath, of the University of Birmingham will discuss how his team used the Lunaphore COMET™ system to conduct a multiplex immunohistochemistry analysis of 30 markers to characterize the processes that drive COVID-19 placentitis. Utilizing spatial biology methods, the present study found that COVID-19 placentitis is characterized by direct infection of the villous trophoblast, histiocytic intervillousitis and associated CXCL10 & interferon mediated inflammation1.
Read the full abstract here and view the presentation details below.
Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting: The morpho-molecular features of COVID-19 placentitis: A high dimensional, multi-omic approach
Date and time: Saturday, November 13; 1:30 – 2:00 p.m. EST | 7:30 – 8:00 p.m. CET
Speaker: Matthew Pugh, FRCPath. (Institute of Immunology and Immunotherapy, University of Birmingham)
In-booth product demonstrations
Lunaphore will also feature its LabSat® and COMET™ spatial biology solutions at booth #408. Live product demonstrations will take place:
- Friday, November 12; 1:30 – 2:00 p.m. and 6:00-6:30 p.m. EST
- Saturday, November 13; 1:00 – 1:30 p.m. and 6:00-6:30 p.m. EST
To learn more about LabSat®, please visit: https://lunaphore.com/products/labsat/.
To learn more about COMET™, please visit: https://lunaphore.com/products/comet/.
To find out more about Lunaphore's activities on site, please visit: https://lunaphore.com/news/lunaphore-at-sitc-annual-meeting/.
Disclaimer:
1 The research is not yet published or peer-reviewed.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006114/en/
Contact information
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of Xella to Holcim20.10.2025 07:40:00 EEST | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund X, LP of a binding agreement to sell Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. The transaction values Xella at approximately €1.85 billion. Headquartered in Duisburg, Germany, Xella is a European provider of efficient and sustainable walling solutions for the entire house shell, operating brands such as Ytong, Silka, Hebel and Multipor. The company employs more than 4,000 team members. In partnership with Lone Star, Xella has taken significant strides in recent years to optimize its offering by strategically focusing the business on walling solutions, while also enhancing its commercial and digital capabilities. Under Lone Star’s stewardship, Xella has also continued to progress its sustainability initiatives. Today, the business stands as a market leader in its sector with a strong reputation for a people-first c
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 07:00:00 EEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom